Payment overview · 2025
General Payments
$44.03
2 reported records · 2 companies
Healthcare provider profile · identity verified
Brian D Wolfe, MD
Allopathic & Osteopathic Physicians|Family Medicine · IOLA, KS · NPI 1396749172
Verified facts
What the public records show
CMS Open Payments records show Brian D Wolfe, MD received $44.03 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 60.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.74 | 60.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.29 | 39.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $44.03 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 74 |
| Lisinopril | Lisinopril | 377 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 297 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 55 |
| Furosemide | Furosemide | 221 | 46 |
| Omeprazole | Omeprazole | 215 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 52 |
| Sertraline Hcl | Sertraline Hcl | 183 | 34 |
| Potassium Chloride | Potassium Chloride | 168 | 37 |
| Pregabalin | Pregabalin | 163 | 33 |
| Losartan Potassium | Losartan Potassium | 162 | 31 |
| Ozempic | Semaglutide | 148 | 29 |
| Gabapentin | Gabapentin | 144 | 32 |
| Alprazolam | Alprazolam | 142 | 30 |
| Metformin Hcl Er | Metformin Hcl | 140 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 125 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 35 |
| Simvastatin | Simvastatin | 116 | 33 |
| Famotidine | Famotidine | 113 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 21 |
| Carvedilol | Carvedilol | 101 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 39 |
| Metformin Hcl | Metformin Hcl | 95 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 24 |
| Allopurinol | Allopurinol | 90 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 19 |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 72 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 17 |
| Spironolactone | Spironolactone | 69 | 23 |
| Xarelto | Rivaroxaban | 67 | 14 |
| Prednisone | Prednisone | 64 | 42 |
| Farxiga | Dapagliflozin Propanediol | 62 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 12 |
| Buspirone Hcl | Buspirone Hcl | 61 | 13 |
| Digoxin | Digoxin | 60 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 58 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 15 |
| Meloxicam | Meloxicam | 58 | 26 |
| Clonazepam | Clonazepam | 56 | 13 |
| Bumetanide | Bumetanide | 55 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Eliquis | Apixaban | 51 | 11 |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Nystatin | Nystatin | 47 | 20 |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 21 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 33 |
| Celecoxib | Celecoxib | 39 | 12 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Atenolol | Atenolol | 34 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Methadone Hcl | Methadone Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 16 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 21 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | 11 |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Azithromycin | Azithromycin | 20 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $44.03 · 2 records | ABBVIE INC. | Dexcom G6 Transmitter, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error